HUANGSHAN-TOURISM
14.3.2022 12:38:06 CET | Business Wire | Press release
Huangshan again captured the imagination of guests at the 2022 ITB Berlin, the world's largest travel trade fair. This year’s virtual ITB Berlin, held from March 8 to 10, saw experts and industry representatives from around the world explore and discuss digital, resilient, and responsible solutions for the global tourism industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220314005401/en/
At the event, Huangshan Tourism Development Co., Ltd. (Huangshan Tourism) held a press conference and multimedia presentation to showcase the many attractions of Huangshan, including its prime location, unique landscapes, rich cultural heritage, and well-developed infrastructures to support local tourism.
The presentation covered six highlights that make Huangshan so appealing as a travel destination.
“Travel in Huangshan” showed its access to a transport network connecting key travel hubs in China. “The Beauty of Huangshan” put the spotlight on the spectacular scenery of Huangshan, from mountain landscapes and its characteristic pine trees to the nearby Taiping Lake. “The Food of Huangshan” gave a taste of the local Huizhou cuisine, one of China’s eight major cuisines. "Accommodation in Huangshan" provided an overview of the high-standard international tourist lodging. “Gifts from Huangshan" gave a glimpse of the unique local presents. Finally, “Culture in Huangshan” introduced the audience to the rich range of cultural and creative products that embody the handicraft, heritage, and traditions of the region.
The immersive format of the event and images of Huangshan Mountain and surrounding areas left a striking visual impact on the audience, again stimulating interest in Huangshan as a world-class travel destination that epitomizes the very best of China’s natural beauty and rich cultural heritage.
About Huangshan Tourism
Huangshan Tourism is one of China’s leading listed tourism companies. It covers a wide scope of business in and around the Mount Huangshan Scenic Area in China’s Anhui Province, from scenic spots and hotels to retail, catering, travel agencies, rural tourism, and other services.
Huangshan Tourism is committed to telling the story of Huangshan, Huizhou culture, and promoting the area as a top destination for both domestic and international tourists. The company carries out extensive overseas publicity and promotional activities, with over 150,000 followers across Facebook, Twitter, and Instagram. On New Year’s Day and during the Spring Festival this year, Huangshan Tourism once again caught the attention of global audiences with activities in Times Square in New York and Trafalgar Square in London.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005401/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Thales Builds Cryptographic Security for the Age of AI and Post-Quantum Computing14.9.2026 09:00:00 CEST | Press release
Thales launches Luna 8, a new hardware security module (HSM) to provide future-ready, quantum resistant security to protect critical data and applications Powered by a Thales designed cryptographic processor, it delivers unparalleled performance, enhanced protection and the flexibility to adapt to new security needs Drawing on decades of cryptographic expertise, Luna 8 combines trusted security with support for emerging technologies, including post quantum cryptography According to the 2026 Thales Data Threat Report, the threat of Harvest Now, Decrypt Later (HNDL) attacks was the top-cited risk, with 59% of organizations reporting that they are prototyping and evaluating post-quantum cryptography (PQC) algorithms to prepare for the quantum era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804748922/en/ ©Thales To help organizations turn this readiness into deployment,Thales, a global leader in advanced technologies, tod
U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations14.9.2026 09:00:00 CEST | Press release
Acceptance is based on pivotal Phase 3 data demonstrating rapid, durable and consistent skin clearance, including in high-impact sites, in a convenient once-daily pill Results from nearly 3,000 patients support potential for next-generation TYK2 inhibitor to redefine oral treatment expectations in psoriasis The Prescription Drug User Fee Act (PDUFA) target action date is in the first quarter of calendar year 2027 Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque psoriasis studies.1-3 Addressing unmet needs in psoriasis treatment “Despite progress in psoriasis care, there remains a need for highly
SWISSto12 and Mitsubishi Electric Corporation Announce Strategic Partnership14.9.2026 09:00:00 CEST | Press release
The Memorandum of Understanding (MoU) and additional contract signal a new phase of collaboration on market development in the Asia Pacific (APAC) region SWISSto12 today announced a memorandum of understanding (MoU) with Mitsubishi Electric Corporation (MELCO) (TOKYO: 6503) to pursue joint opportunities on advanced payloads, radio frequency (RF) products, and market development in Japan and the APAC region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260914982179/en/ Masahiko Arai, Executive Officer and Group President, Defense & Space Systems, Mitsubishi Electric, and Dr. Emile de Rijk, Chief Executive Officer, SWISSto12 Joint opportunities will leverage MELCO’s extensive satellite system expertise and integration capabilities together with SWISSto12’s proprietary 3D-printing designs and processes that form the foundation of its next-generation payloads—smaller, lighter, highly performant, yet built in materially shorter
Focused Support Launches Cavok STRIKE to Expand Link-16 Participation Across the Joint Force14.9.2026 07:00:00 CEST | Press release
Extending Link-16 interoperability without platform-level hardware integration Focused Support LLC today announced the launch of Cavok STRIKE, an integrated software capability that expands the Link-16 tactical battlespace picture by enabling additional operational platforms to participate in the Link-16 network. Modern battlefields have increasing numbers of unmanned systems, sensors, and supporting platforms operating throughout the joint battlespace. The rapid proliferation of Group 1, 2, and 3 UAS, including both expendable and recoverable systems, has created a growing need to integrate these assets into the broader tactical network. Many of these platforms provide operationally relevant information but have historically remained outside the Link-16 network due to limitations in size, weight, power, platform integration complexity, or acquisition cost. Cavok STRIKE addresses this gap by enabling platforms to participate in the Link-16 network as non-command-and-control participant
Fujirebio Expands Access to Blood-based Neurology Testing in Brazil with ANVISA Market Authorization for Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma14.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that the Brazilian Health Regulatory Agency (ANVISA) has granted market authorization for the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for use on the fully automated LUMIPULSE® G immunoassay platform in Brazil. “ANVISA authorization of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays marks another important step in our mission to expand access to reliable, clinically meaningful blood-based biomarkers for clinicians and patients worldwide,” said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “By making both neurological biomarker assays available to laboratories on a single, fully automated platform, we are helping support more informed clinical decision-making across a broad range of neurological conditions and throughout the diagnostic pathway.” The Brazilian ANVISA authorizations are based on the already CE marked in vitro diagnostics (IVD) approvals of these two
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom